These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38805731)

  • 1. Hepatocellular Carcinoma Assessment after Locoregional Treatment: A Primer on LI-RADS Contrast-Enhanced Nonradiation Treatment Response Assessment Version 2024.
    Milot L
    Radiology; 2024 May; 311(2):e240124. PubMed ID: 38805731
    [No Abstract]   [Full Text] [Related]  

  • 2. Liver Imaging Reporting and Data System Contrast-Enhanced US Nonradiation Treatment Response Assessment Version 2024.
    Lyshchik A; Fetzer DT; Kono Y; Wilson SR; Dietrich CF; Clevert DA; Meloni MF; Jang HJ; Kim TK; Lee JM; Minami Y; Kudo M; Piscaglia F
    Radiology; 2024 May; 311(2):e232369. PubMed ID: 38805727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of LI-RADS Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma in Liver Transplant Candidates: Intraindividual Comparison between CT and Hepatobiliary Agent-enhanced MRI.
    Bae JS; Lee JM; Yoon JH; Kang HJ; Jeon SK; Joo I; Lee KB; Kim H
    Radiology; 2021 May; 299(2):336-345. PubMed ID: 33650901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm.
    Kielar A; Fowler KJ; Lewis S; Yaghmai V; Miller FH; Yarmohammadi H; Kim C; Chernyak V; Yokoo T; Meyer J; Newton I; Do RK
    Abdom Radiol (NY); 2018 Jan; 43(1):218-230. PubMed ID: 28780679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Common pitfalls when using the Liver Imaging Reporting and Data System (LI-RADS): lessons learned from a multi-year experience.
    Cannella R; Fowler KJ; Borhani AA; Minervini MI; Heller M; Furlan A
    Abdom Radiol (NY); 2019 Jan; 44(1):43-53. PubMed ID: 30073400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) 2017 - a review of important differences compared to the CT/MRI system.
    Kim TK; Noh SY; Wilson SR; Kono Y; Piscaglia F; Jang HJ; Lyshchik A; Dietrich CF; Willmann JK; Vezeridis A; Sirlin CB
    Clin Mol Hepatol; 2017 Dec; 23(4):280-289. PubMed ID: 28911220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incorporation of Ancillary MRI Features Into the LI-RADS Treatment Response Algorithm: Impact on Diagnostic Performance After Locoregional Treatment of Hepatocellular Carcinoma.
    Kim YY; Kim MJ; Yoon JK; Shin J; Roh YH
    AJR Am J Roentgenol; 2022 Mar; 218(3):484-493. PubMed ID: 34585608
    [No Abstract]   [Full Text] [Related]  

  • 8. LI-RADS
    Chernyak V; Santillan CS; Papadatos D; Sirlin CB
    Abdom Radiol (NY); 2018 Jan; 43(1):111-126. PubMed ID: 28695233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: Imaging for Diagnosis, Tumor Response to Treatment and Liver Response to Radiation.
    Lo EC; N Rucker A; Federle MP
    Semin Radiat Oncol; 2018 Oct; 28(4):267-276. PubMed ID: 30309637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management implications and outcomes of LI-RADS-2, -3, -4, and -M category observations.
    Mitchell DG; Bashir MR; Sirlin CB
    Abdom Radiol (NY); 2018 Jan; 43(1):143-148. PubMed ID: 28779335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma.
    Fowler KJ; Potretzke TA; Hope TA; Costa EA; Wilson SR
    Abdom Radiol (NY); 2018 Jan; 43(1):149-157. PubMed ID: 28580538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bifocal hepatocellular carcinoma: Magnetic resonance imaging features after transarterial embolization.
    Picchia S; Bali MA
    Curr Probl Cancer; 2018; 42(3):319-321. PubMed ID: 29729826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.
    Terzi E; Iavarone M; Pompili M; Veronese L; Cabibbo G; Fraquelli M; Riccardi L; De Bonis L; Sangiovanni A; Leoni S; Zocco MA; Rossi S; Alessi N; Wilson SR; Piscaglia F;
    J Hepatol; 2018 Mar; 68(3):485-492. PubMed ID: 29133247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updates on LI-RADS Treatment Response Criteria for Hepatocellular Carcinoma: Focusing on MRI.
    Patel R; Aslam A; Parikh ND; Mervak B; Mubarak E; Higgins L; Lala K; Conner JF; Khaykin V; Bashir M; Do RKG; Burke LMB; Smith EN; Kim CY; Shampain KL; Owen D; Mendiratta-Lala M
    J Magn Reson Imaging; 2023 Jun; 57(6):1641-1654. PubMed ID: 36872608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017.
    Seo N; Kim MS; Park MS; Choi JY; Do RKG; Han K; Kim MJ
    Eur Radiol; 2020 Jan; 30(1):261-271. PubMed ID: 31418085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LI-RADS version 2018 treatment response algorithm on extracellular contrast-enhanced MRI in patients treated with transarterial chemoembolization for hepatocellular carcinoma: diagnostic performance and the added value of ancillary features.
    Wang D; Zhang Y; Lyu R; Jia K; Xu PJ
    Abdom Radiol (NY); 2024 Sep; 49(9):3045-3055. PubMed ID: 38605217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging After Locoregional Therapy for Hepatocellular Carcinoma With Emphasis on LIRADS Treatment Response Assessment Criteria.
    Bajaj G; Sundaram K; Jambhekar K; Ram R
    Semin Ultrasound CT MR; 2021 Aug; 42(4):390-404. PubMed ID: 34130851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LI-RADS-CEUS - Proposal for a Contrast-Enhanced Ultrasound Algorithm for the Diagnosis of Hepatocellular Carcinoma in High-Risk Populations.
    Schellhaas B; Wildner D; Pfeifer L; Goertz RS; Hagel A; Neurath MF; Strobel D
    Ultraschall Med; 2016 Dec; 37(6):627-634. PubMed ID: 27486793
    [No Abstract]   [Full Text] [Related]  

  • 19. Liver Imaging Reporting and Data System: Discordance Between Computed Tomography and Gadoxetate-Enhanced Magnetic Resonance Imaging for Detection of Hepatocellular Carcinoma Major Features.
    Chernyak V; Flusberg M; Law A; Kobi M; Paroder V; Rozenblit AM
    J Comput Assist Tomogr; 2018; 42(1):155-161. PubMed ID: 28806321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multimodality Imaging of Hepatocellular Carcinoma: From Diagnosis to Treatment Response Assessment in Everyday Clinical Practice.
    Delli Pizzi A; Mastrodicasa D; Cianci R; Serafini FL; Mincuzzi E; Di Fabio F; Giammarino A; Mannetta G; Basilico R; Caulo M
    Can Assoc Radiol J; 2021 Nov; 72(4):714-727. PubMed ID: 32436394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.